Janux Therapeutics (JANX) EBITDA (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of EBITDA data on file, last reported at -$34.2 million in Q1 2026.

• On a quarterly basis, EBITDA rose 1.96% year-over-year to -$34.2 million in Q1 2026; TTM through Mar 2026 was -$157.0 million, a 38.21% decrease from a year earlier, with the FY2025 full-year figure at -$157.7 million, down 59.51% from the prior year.
• EBITDA for Q1 2026 stood at -$34.2 million, up from -$42.4 million in the prior quarter.
• Over the last five years, EBITDA for JANX reached as high as -$13.5 million in Q1 2022 and fell as low as -$45.1 million in Q2 2025.
• Historically, EBITDA has averaged -$25.3 million across 5 years, with a median of -$20.3 million in 2023.
• Across the five-year window, EBITDA sank 492.91% in 2022 and surged 33.38% in 2024, its largest moves.
• Year by year, EBITDA stood at -$18.3 million in 2022, then climbed by 11.66% to -$16.1 million in 2023, then slumped by 79.85% to -$29.0 million in 2024, then sank by 46.1% to -$42.4 million in 2025, then gained by 19.31% to -$34.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$34.2 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.